These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 27428375)

  • 21. Prevalence and spectrum of BRCA germline variants in mainland Chinese familial breast and ovarian cancer patients.
    Kim YC; Zhao L; Zhang H; Huang Y; Cui J; Xiao F; Downs B; Wang SM
    Oncotarget; 2016 Feb; 7(8):9600-12. PubMed ID: 26848529
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Germline and tumor BRCA1/2 pathogenic variants in Chinese triple-negative breast carcinomas.
    Ji G; Bao L; Yao Q; Zhang J; Zhu X; Bai Q; Shao Z; Yang W; Zhou X
    J Cancer Res Clin Oncol; 2021 Oct; 147(10):2935-2944. PubMed ID: 34254208
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Communication processes about predictive genetic testing within high-risk breast cancer families: a two-phase study design.
    Blomen CL; Pott A; Volk AE; Budäus L; Witzel I
    Sci Rep; 2021 Oct; 11(1):20178. PubMed ID: 34635688
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Smoking and risk of breast cancer in carriers of mutations in BRCA1 or BRCA2 aged less than 50 years.
    ; ;
    Breast Cancer Res Treat; 2008 May; 109(1):67-75. PubMed ID: 17972172
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Men at risk of being a mutation carrier for hereditary breast/ovarian cancer: an exploration of attitudes and psychological functioning during genetic testing.
    Lodder L; Frets PG; Trijsburg RW; Tibben A; Meijers-Heijboer EJ; Duivenvoorden HJ; Wagner A; van Der Meer CA; Devilee P; Cornelisse CJ; Niermeijer MF
    Eur J Hum Genet; 2001 Jul; 9(7):492-500. PubMed ID: 11464240
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The spectrum of BRCA mutations and characteristics of BRCA-associated breast cancers in China: Screening of 2,991 patients and 1,043 controls by next-generation sequencing.
    Lang GT; Shi JX; Hu X; Zhang CH; Shan L; Song CG; Zhuang ZG; Cao AY; Ling H; Yu KD; Li S; Sun MH; Zhou XY; Huang W; Shao ZM
    Int J Cancer; 2017 Jul; 141(1):129-142. PubMed ID: 28294317
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Contralateral breast cancer after radiotherapy among BRCA1 and BRCA2 mutation carriers: a WECARE study report.
    Bernstein JL; Thomas DC; Shore RE; Robson M; Boice JD; Stovall M; Andersson M; Bernstein L; Malone KE; Reiner AS; Lynch CF; Capanu M; Smith SA; Tellhed L; Teraoka SN; Begg CB; Olsen JH; Mellemkjaer L; Liang X; Diep AT; Borg A; Concannon P; Haile RW;
    Eur J Cancer; 2013 Sep; 49(14):2979-85. PubMed ID: 23706288
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Breast cancer risk factors differ between Asian and white women with BRCA1/2 mutations.
    de Bruin MA; Kwong A; Goldstein BA; Lipson JA; Ikeda DM; McPherson L; Sharma B; Kardashian A; Schackmann E; Kingham KE; Mills MA; West DW; Ford JM; Kurian AW
    Fam Cancer; 2012 Sep; 11(3):429-39. PubMed ID: 22638769
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Analysis of the pathogenic variants of BRCA1 and BRCA2 using next-generation sequencing in women with familial breast cancer: a case-control study.
    Zayas-Villanueva OA; Campos-Acevedo LD; Lugo-Trampe JJ; Hernández-Barajas D; González-Guerrero JF; Noriega-Iriondo MF; Ramírez-Sánchez IA; Martínez-de-Villarreal LE
    BMC Cancer; 2019 Jul; 19(1):722. PubMed ID: 31331294
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Risk of ipsilateral breast tumor recurrence in primary invasive breast cancer following breast-conserving surgery with BRCA1 and BRCA2 mutation in China.
    Cao W; Xie Y; He Y; Li J; Wang T; Fan Z; Fan T; Ouyang T
    Breast Cancer Res Treat; 2019 Jun; 175(3):749-754. PubMed ID: 30895535
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparing the frequency of common genetic variants and haplotypes between carriers and non-carriers of BRCA1 and BRCA2 deleterious mutations in Australian women diagnosed with breast cancer before 40 years of age.
    Turkovic L; Gurrin LC; Bahlo M; Dite GS; Southey MC; Hopper JL
    BMC Cancer; 2010 Sep; 10():466. PubMed ID: 20807450
    [TBL] [Abstract][Full Text] [Related]  

  • 32. DNA-testing for BRCA1/2 prior to genetic counselling in patients with breast cancer: design of an intervention study, DNA-direct.
    Sie AS; Spruijt L; van Zelst-Stams WA; Mensenkamp AR; Ligtenberg MJ; Brunner HG; Prins JB; Hoogerbrugge N
    BMC Womens Health; 2012 May; 12():12. PubMed ID: 22569005
    [TBL] [Abstract][Full Text] [Related]  

  • 33. BRCA1 and BRCA2 mutations as prognostic factors in bilateral breast cancer patients.
    Rogozińska-Szczepka J; Utracka-Hutka B; Grzybowska E; Maka B; Nowicka E; Smok-Ragankiewicz A; Zientek H; Steffen J; Wojciechowska-Łacka A
    Ann Oncol; 2004 Sep; 15(9):1373-6. PubMed ID: 15319244
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [BRCA1 and BRCA2 gene mutations of familial breast cancer from Shanghai in China].
    Song CG; Hu Z; Yuan WT; Di GH; Shen ZZ; Huang W; Shao ZM
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2006 Feb; 23(1):27-31. PubMed ID: 16456781
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Participation of Korean families at high risk for hereditary breast and ovarian cancer in BRCA1/2 genetic testing.
    Sun Y; Kang E; Baek H; Jung J; Hwang E; Koo J; Kim EK; Kim SW
    Jpn J Clin Oncol; 2015 Jun; 45(6):527-32. PubMed ID: 25838294
    [TBL] [Abstract][Full Text] [Related]  

  • 36. BRCA mutation-negative women from hereditary breast and ovarian cancer families: a qualitative study of the BRCA-negative experience.
    Bakos AD; Hutson SP; Loud JT; Peters JA; Giusti RM; Greene MH
    Health Expect; 2008 Sep; 11(3):220-31. PubMed ID: 18816319
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adjuvant systemic therapy for breast cancer in BRCA1/BRCA2 mutation carriers in a population-based study of risk of contralateral breast cancer.
    Reding KW; Bernstein JL; Langholz BM; Bernstein L; Haile RW; Begg CB; Lynch CF; Concannon P; Borg A; Teraoka SN; Törngren T; Diep A; Xue S; Bertelsen L; Liang X; Reiner AS; Capanu M; Malone KE;
    Breast Cancer Res Treat; 2010 Sep; 123(2):491-8. PubMed ID: 20135344
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bias Explains Most of the Parent-of-Origin Effect on Breast Cancer Risk in BRCA1/2 Mutation Carriers.
    Vos JR; Oosterwijk JC; Aalfs CM; Rookus MA; Adank MA; van der Hout AH; van Asperen CJ; Gómez Garcia EB; Mensenkamp AR; Jager A; Ausems MG; Mourits MJ; de Bock GH;
    Cancer Epidemiol Biomarkers Prev; 2016 Aug; 25(8):1251-8. PubMed ID: 27277847
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevalence and characterization of ATM germline mutations in Chinese BRCA1/2-negative breast cancer patients.
    Yang Z; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Zhang J; Xie Y
    Breast Cancer Res Treat; 2019 Apr; 174(3):639-647. PubMed ID: 30607632
    [TBL] [Abstract][Full Text] [Related]  

  • 40. BRCA1 and BRCA2 mutations in ovarian cancer patients from China: ethnic-related mutations in BRCA1 associated with an increased risk of ovarian cancer.
    Shi T; Wang P; Xie C; Yin S; Shi D; Wei C; Tang W; Jiang R; Cheng X; Wei Q; Wang Q; Zang R
    Int J Cancer; 2017 May; 140(9):2051-2059. PubMed ID: 28176296
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.